Tier 4 — mechanistic

Fisetin to Reduce Senescence and Mobility Impairment in Peripheral Artery Disease: The FIRST Pilot Randomized Trial

Mary M. McDermott
ClinicalTrials.gov trial registry record 2024

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Sponsor: Northwestern University. Public registry materials identify the academic sponsor; full grant funding details are not provided in this record.
Competing interests
Not reported in the registry record.

Study snapshot

DesignPhase 2 pilot randomized placebo-controlled trial.
ModelAdults aged 50 years and older with peripheral artery disease and mobility impairment.
SampleEstimated enrollment: 34 participants.
InterventionFisetin approximately 20 mg/kg once daily for 2 consecutive days every 14 days, rounded to available capsule strength, versus matched placebo.
DurationRepeated short-course dosing over approximately four months.
Endpoints6-minute walk distance; Senescence-related markers in adipose tissue, skeletal muscle and blood; Inflammatory markers; Safety and tolerability

What the study showed, in plain terms

FIRST tests whether intermittent fisetin can improve walking performance and alter senescence-related biology in people with peripheral artery disease. Participants receive short two-day courses every two weeks.

The trial is recruiting and has no posted efficacy results. It is important because it directly links a mobility endpoint with tissue and blood senescence markers, but it does not yet show that fisetin improves PAD or walking capacity.

Key findings

  • Estimated enrollment is 34 participants aged 50 years or older with PAD.
  • The intervention uses repeated two-day fisetin courses approximately every two weeks.
  • The trial measures both 6-minute walk performance and senescence/inflammation biomarkers.

What this study can and cannot tell us

  • No results are posted yet.
  • Small pilot design limits precision.
  • PAD-specific findings may not generalize to healthy aging or other vascular conditions.

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology